Estudio de la expresión de genes en cacao mediadas por la levadura (saccharomyces cerevisiae), para mejorar la producción de manteca de cacao

Cocoa butter can be used as a raw material in the production of chocolates, cosmetics, fuels, among other products. This has generated an increase in the demand for MC, in such a way that it triggered a shortage of manufactured products due to their insufficiency. Numerous studies have been carried out in relation to CM, where several non-oleaginous and oleaginous yeast strains were analyzed under nitrogen-limited culture conditions. For the extraction of the different strains, they used non-oleaginous and oleaginous S. cerevisiae, which were subjected to analyzes, in which the great potential of this yeast could be determined. Currently, synthetic biotechnology, metabolic engineering and genetic engineering have allowed the production of a high level of triacylglycerols (TAG) equivalent to MC, by means of fermenting microorganisms such as yeast. This, in order to measure the production capacity of lipids similar to butter in the biosynthesis of TAGs. Saccharomyces cerevisiae produces TAGs as storage lipids, which consist of C16 and C18 fatty acids. However, cocoa butter-like lipids (CBL, which are made up of POP, POS, and SOS) are not among the main forms of TAG in yeast. However, Saccharomyces cerevisiae yeast strains have been designed with a modified synthesis of fatty acids. By expressing the selected cocoa genes in S. cerevisiae by molecular transformation, the total fatty acid production of TAG and CBL was successfully increased.  La manteca de cacao puede utilizarse como materia prima en la producción de chocolates, cosméticos, combustibles entre otros productos. Esto ha generado un aumento en la demanda de MC, de tal forma que a desencadenó en una escasez de productos elaborados debido a su insuficiencia. Se han realizado numerosos estudios con relación a la MC, donde se analizaron varias cepas de levaduras no oleaginosas y oleaginosas en condiciones de cultivo limitadas en nitrógeno. Para la extracción de las diferentes cepas, utilizaron S. Cerevisiae no oleaginosa y oleaginosa, que fueron sujetas a análisis, en los cuales se pudo determinar el gran potencial de esta levadura. Actualmente la biotecnología sintética, ingeniería metabólica y la ingeniería genética, han permitido la producción de un alto nivel de triacilgliceroles (TAG) equivalentes a la MC, mediante microrganismos fermentadores como las levaduras. Esto, con el fin de medir la capacidad de producción de lípidos similares a la manteca en la biosíntesis de TAGs. La Saccharomyces cerevisiae produce TAG como lípidos de almacenamiento, que consisten en ácidos grasos C16 y C18. Sin embargo, los lípidos similares a la manteca de cacao (CBL, que se componen de POP, POS y SOS) no se encuentran entre las principales formas de TAG en la levadura. No obstante, se han diseñado cepas de levadura Saccharomyces Cerevisiae con una síntesis modificada de ácidos grasos. Al expresar los genes de cacao seleccionados en S. cerevisiae mediante transformación molecular, se aumentó con éxito la producción total de ácidos grasos de TAG y CBL. &nbsp

Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy

While pancreatic cancer (PC) survival rates have recently shown modest improvement, the disease remains largely incurable. Early detection of pancreatic cancer may result in improved outcomes and therefore, methods for early detection of cancer, even premalignant lesions, may provide more favorable outcomes. Pancreatic intraepithelial neoplasias (PanINs) have been identified as premalignant precursor lesions to pancreatic cancer. However, conventional imaging methods used for screening high-risk populations do not have the sensitivity to detect PanINs. Here, we have employed hyperpolarized metabolic imaging in vivo and nuclear magnetic resonance (1H-NMR) metabolomics ex vivo to identify and understand metabolic changes, towards enabling detection of early PanINs and progression to advanced PanINs lesions that precede pancreatic cancer formation. Progression of disease from tissue containing predominantly low-grade PanINs to tissue with high-grade PanINs showed a decreasing alanine/lactate ratio from high-resolution NMR metabolomics ex vivo. Hyperpolarized magnetic resonance spectroscopy (HP-MRS) allows over 10,000-fold sensitivity enhancement relative to conventional magnetic resonance. Real-time HP-MRS was employed to measure non-invasively changes of alanine and lactate metabolites with disease progression and in control mice in vivo, following injection of hyperpolarized [1-13C] pyruvate. The alanine-to-lactate signal intensity ratio was found to decrease as the disease progressed from low-grade PanINs to high-grade PanINs. The biochemical changes of alanine transaminase (ALT) and lactate dehydrogenase (LDH) enzyme activity were assessed. These results demonstrate that there are significant alterations of ALT and LDH activities during the transformation from early to advanced PanINs lesions. Furthermore, we demonstrate that real-time conversion kinetic rate constants (kPA and kPL) can be used as metabolic imaging biomarkers of pancreatic premalignant lesions. Findings from this emerging HP-MRS technique can be translated to the clinic for detection of pancreatic premalignant lesion in high-risk populations.Fil: Dutta, Prasanta. University of Texas; Estados UnidosFil: Castro Pando, Susana. University of Texas; Estados UnidosFil: Mascaró, Marilina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Investigaciones Bioquímicas de Bahía Blanca. Universidad Nacional del Sur. Instituto de Investigaciones Bioquímicas de Bahía Blanca; Argentina. University of Texas; Estados UnidosFil: Riquelme, Erick. University of Texas; Estados UnidosFil: Zoltan, Michelle. University of Texas; Estados UnidosFil: Zacharias, Niki M.. University of Texas; Estados UnidosFil: Gammon, Seth T.. University of Texas; Estados UnidosFil: Piwnica-Worms, David. University of Texas; Estados UnidosFil: Pagel, Mark D.. University of Texas; Estados UnidosFil: Sen, Subrata. University of Texas; Estados UnidosFil: Maitra, Anirban. University of Texas; Estados UnidosFil: Shams, Shayan. University of Texas; Estados UnidosFil: McAllister, Florencia. University of Texas; Estados UnidosFil: Bhattacharya, Pratip K.. University of Texas; Estados Unido

Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis

IL17 is required for the initiation and progression of pancreatic cancer, particularly in the context of inflammation, as previously shown by genetic and pharmacological approaches. However, the cellular compartment and downstream molecular mediators of IL17-mediated pancreatic tumorigenesis have not been fully identified. This study examined the cellular compartment required by generating transgenic animals with IL17 receptor A (IL17RA), which was genetically deleted from either the pancreatic epithelial compartment or the hematopoietic compartment via generation of IL17RA-deficient (IL17-RA-/-) bone marrow chimeras, in the context of embryonically activated or inducible Kras. Deletion of IL17RA from the pancreatic epithelial compartment, but not from hematopoietic compartment, resulted in delayed initiation and progression of premalignant lesions and increased infiltration of CD8+ cytotoxic T cells to the tumor microenvironment. Absence of IL17RA in the pancreatic compartment affected transcriptional profiles of epithelial cells, modulating stemness, and immunological pathways. B7-H4, a known inhibitor of T-cell activation encoded by the gene Vtcn1, was the checkpoint molecule most upregulated via IL17 early during pancreatic tumorigenesis, and its genetic deletion delayed the development of pancreatic premalignant lesions and reduced immunosuppression. Thus, our data reveal that pancreatic epithelial IL17RA promotes pancreatic tumorigenesis by reprogramming the immune pancreatic landscape, which is partially orchestrated by regulation of B7-H4. Our findings provide the foundation of the mechanisms triggered by IL17 to mediate pancreatic tumorigenesis and reveal the avenues for early pancreatic cancer immune interception. See related Spotlight by Lee and Pasca di Magliano, p. 1130

Gut Epithelial Interleukin-17 Receptor a Signaling Can Modulate Distant Tumors Growth Through Microbial Regulation

Microbes influence cancer initiation, progression and therapy responsiveness. IL-17 signaling contributes to gut barrier immunity by regulating microbes but also drives tumor growth. A knowledge gap remains regarding the influence of enteric IL-17-IL-17RA signaling and their microbial regulation on the behavior of distant tumors. We demonstrate that gut dysbiosis induced by systemic or gut epithelial deletion of IL-17RA induces growth of pancreatic and brain tumors due to excessive development of Th17, primary source of IL-17 in human and mouse pancreatic ductal adenocarcinoma, as well as B cells that circulate to distant tumors. Microbial dependent IL-17 signaling increases DUOX2 signaling in tumor cells. Inefficacy of pharmacological inhibition of IL-17RA is overcome with targeted microbial ablation that blocks the compensatory loop. These findings demonstrate the complexities of IL-17-IL-17RA signaling in different compartments and the relevance for accounting for its homeostatic host defense function during cancer therapy

Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis

BACKGROUND: Despite a high response rate to chemotherapy, the majority of patients with acute myeloid leukemia (AML) are destined to relapse due to residual disease in the bone marrow (BM). The tumor microenvironment is increasingly being recognized as a critical factor in mediating cancer cell survival and drug resistance. In this study, we propose to identify mechanisms involved in the chemoprotection conferred by the BM stroma to leukemia cells. METHODS: Using a leukemia mouse model and a human leukemia cell line, we studied the interaction of leukemia cells with the BM microenvironment. We evaluated in vivo and in vitro leukemia cell chemoprotection to different cytotoxic agents mediated by the BM stroma. Leukemia cell apoptosis was assessed by flow cytometry and western blotting. The activity of the equilibrative nucleoside transporter 1 (ENT1), responsible for cytarabine cell incorporation, was investigated by measuring transport and intracellular accumulation of (3)H-adenosine. RESULTS: Leukemia cell mobilization from the bone marrow into peripheral blood in vivo using a CXCR4 inhibitor induced chemo-sensitization of leukemia cells to cytarabine, which translated into a prolonged survival advantage in our mouse leukemia model. In vitro, the BM stromal cells secreted a soluble factor that mediated significant chemoprotection to leukemia cells from cytarabine induced apoptosis. Furthermore, the BM stromal cell supernatant induced a 50% reduction of the ENT1 activity in leukemia cells, reducing the incorporation of cytarabine. No protection was observed when radiation or other cytotoxic agents such as etoposide, cisplatin and 5-fluorouracil were used. CONCLUSION: The BM stroma secretes a soluble factor that significantly protects leukemia cells from cytarabine-induced apoptosis and blocks ENT1 activity. Strategies that modify the chemo-protective effects mediated by the BM microenvironment may enhance the benefit of conventional chemotherapy for patients with AML

Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells

Sjögren’s disease is a complex autoimmune disease with twelve established susceptibility loci. This genome-wide association study (GWAS) identifies ten novel genome-wide significant (GWS) regions in Sjögren’s cases of European ancestry: CD247, NAB1, PTTG1-MIR146A, PRDM1-ATG5, TNFAIP3, XKR6, MAPT-CRHR1, RPTOR-CHMP6-BAIAP6, TYK2, SYNGR1. Polygenic risk scores yield predictability (AUROC = 0.71) and relative risk of 12.08. Interrogation of bioinformatics databases refine the associations, define local regulatory networks of GWS SNPs from the 95% credible set, and expand the implicated gene list to >40. Many GWS SNPs are eQTLs for genes within topologically associated domains in immune cells and/or eQTLs in the main target tissue, salivary glands.Research reported in this publication was supported by the National Institutes of Health (NIH): R01AR073855 (C.J.L.), R01AR065953 (C.J.L.), R01AR074310 (A.D.F.), P50AR060804 (K.L.S.), R01AR050782 (K.L.S), R01DE018209 (K.L.S.), R33AR076803 (I.A.), R21AR079089 (I.A.); NIDCR Sjögren’s Syndrome Clinic and Salivary Disorders Unit were supported by NIDCR Division of Intramural Research at the National Institutes of Health funds - Z01-DE000704 (B.W.); Birmingham NIHR Biomedical Research Centre (S.J.B.); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC 2155 – Projektnummer 390874280 (T.W.); Research Council of Norway (Oslo, Norway) – Grant 240421 (TR.R.), 316120 (M.W-H.); Western Norway Regional Health Authority (Helse Vest) – 911807, 912043 (R.O.); Swedish Research Council for Medicine and Health (L.R., G.N., M.W-H.); Swedish Rheumatism Association (L.R., G.N., M.W-H.); King Gustav V’s 80-year Foundation (G.N.); Swedish Society of Medicine (L.R., G.N., M.W-H.); Swedish Cancer Society (E.B.); Sjögren’s Syndrome Foundation (K.L.S.); Phileona Foundation (K.L.S.). The Stockholm County Council (M.W-H.); The Swedish Twin Registry is managed through the Swedish Research Council - Grant 2017-000641. The French ASSESS (Atteinte Systémique et Evolution des patients atteints de Syndrome de Sjögren primitive) was sponsored by Assistance Publique-Hôpitaux de Paris (Ministry of Health, PHRC 2006 P060228) and the French society of Rheumatology (X.M.).publishedVersio

Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.

Sjögren’s disease is a complex autoimmune disease with twelve established susceptibility loci. This genome-wide association study (GWAS) identifies ten novel genome-wide significant (GWS) regions in Sjögren’s cases of European ancestry: CD247, NAB1, PTTG1-MIR146A, PRDM1-ATG5, TNFAIP3, XKR6, MAPT-CRHR1, RPTOR-CHMP6-BAIAP6, TYK2, SYNGR1. Polygenic risk scores yield predictability (AUROC = 0.71) and relative risk of 12.08. Interrogation of bioinformatics databases refine the associations, define local regulatory networks of GWS SNPs from the 95% credible set, and expand the implicated gene list to >40. Many GWS SNPs are eQTLs for genes within topologically associated domains in immune cells and/or eQTLs in the main target tissue, salivary glands.We thank all the research and clinical staff, consortium investigators, and study participants (detailed in Supplementary Information), and funding agencies who made this study possible. The content of this publication is solely the responsibility of the authors and does not represent the official views of the funding agencies listed below. Research reported in this publication was supported by the National Institutes of Health (NIH): R01AR073855 (C.J.L.), R01AR065953 (C.J.L.), R01AR074310 (A.D.F.), P50AR060804 (K.L.S.), R01AR050782 (K.L.S), R01DE018209 (K.L.S.), R33AR076803 (I.A.), R21AR079089 (I.A.); NIDCR Sjögren’s Syndrome Clinic and Salivary Disorders Unit were supported by NIDCR Division of Intramural Research at the National Institutes of Health funds - Z01-DE000704 (B.W.); Birmingham NIHR Biomedical Research Centre (S.J.B.); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC 2155 – Projektnummer 390874280 (T.W.); Research Council of Norway (Oslo, Norway) – Grant 240421 (TR.R.), 316120 (M.W-H.); Western Norway Regional Health Authority (Helse Vest) – 911807, 912043 (R.O.); Swedish Research Council for Medicine and Health (L.R., G.N., M.W-H.); Swedish Rheumatism Association (L.R., G.N., M.W-H.); King Gustav V’s 80-year Foundation (G.N.); Swedish Society of Medicine (L.R., G.N., M.W-H.); Swedish Cancer Society (E.B.); Sjögren’s Syndrome Foundation (K.L.S.); Phileona Foundation (K.L.S.). The Stockholm County Council (M.W-H.); FOREUM Foundation for Research in Rheumatology (R.J., M.W-H). The Swedish Twin Registry is managed through the Swedish Research Council - Grant 2017-000641. The French ASSESS (Atteinte Systémique et Evolution des patients atteints de Syndrome de Sjögren primitive) was sponsored by Assistance Publique-Hôpitaux de Paris (Ministry of Health, PHRC 2006 P060228) and the French society of Rheumatology (X.M.). We want to acknowledge the following invesigators who recruited patients: Jacques-Eric Gottenberg, Valerie Devauchelle-Pensec, Jean Jacques Dubost, Anne-Laure Fauchais, Vincent Goeb, Eric Hachulla, Claire Larroche, Véronique Le Guern, Jacques Morel, Aleth Perdriger, Emmanuelle Dernis, Stéphanie Rist, Damien Sene, Olivier Vittecoq. We also thank Sarah Tubiana and all staff members of the Bichat Hospital Biological Resource Center (Paris) for centralizing and managing biological collection. We also thank Rezvan Kiani Dehkordi, Karolina Tandre, Käth Nilsson, Marianne Eidsheim, Kjerstin Jacobsen, Ingeborg Kvivik and Kjetil Bårdsen for collecting patient blood samples. We acknowledge the SNP&SEQ Technology Platform, Uppsala, part of National Genomics Infrastructure (NGI) Sweden, for genotyping of Scandinavian samples, and the Swedish Twin Registry for access to data. The SNP&SEQ Technology Platform was supported by Science for Life Laboratory, Uppsala University, the Knut and Alice Wallenberg Foundation and the Swedish Research Council. Last, we thank the investigators for the following dbGaP studies: Phs000428.v2.p2: This study used control data from the Health and Retirement Study in dbGaP (phs000428.v2.p2) submitted by David Weir, PhD at the University of Michigan and funded by the National Institute of Aging RC2 AG036495 and RC4 AG039029. Phs000672.v1.p1: Genotype data from the Sjögren’s International Collaborative Clinical Alliance (SICCA) Registry was obtained through dbGAP accession number phs000672.v1.p1. This study was supported by the National Institute of Dental and Craniofacial Research (NIDCR), the National Eye Institute, and the Office of Research on Women’s Health through contract number N01-DE-32636. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health (NIH) to the Johns Hopkins University (contract numbers HHSN268200782096C, HHSN268201100011I, HHSN268201200008I). Funds for genotyping were provided by the NIDCR through CIDR’s NIH contract. Assistance with data cleaning and imputation was provided by the University of Washington. We thank investigators from the following studies that provided DNA samples for genotyping: the Genetic Architecture of Smoking and Smoking Cessation, Collaborative Genetic Study of Nicotine Dependence (phs000404.v1.p1); Age-Related Eye Disease Study (AREDS) - Genetic Variation in Refractive Error Substudy (phs000429.v1.p1); and National Institute of Mental Health’s Human Genetics Initiative (phs000021.v3.p2, phs000167.v1.p1). We thank the many clinical collaborators and research participants who contributed to this research. Phs000196.v3.p1: Investigators and Parkinson Disease patients that contributed to this Genome-wide Association Study of Parkinson Disease. phs000187.v1.p1: Research support to collect data and develop an application to support the High Density SNP Association Analysis of Melanoma project was provided by 3P50CA093459, 5P50CA097007, 5R01ES011740, and 5R01CA133996

Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren's syndrome

Objective: Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE) are related by clinical and serologic manifestations as well as genetic risks. Both diseases are more commonly found in women than in men, at a ratio of ~10 to 1. Common X chromosome aneuploidies, 47,XXY and 47,XXX, are enriched among men and women, respectively, in either disease, suggesting a dose effect on the X chromosome. Methods: We examined cohorts of SS and SLE patients by constructing intensity plots of X chromosome single-nucleotide polymorphism alleles, along with determining the karyotype of selected patients. Results: Among ~2,500 women with SLE, we found 3 patients with a triple mosaic, consisting of 45,X/46,XX/47,XXX. Among ~2,100 women with SS, 1 patient had 45,X/46,XX/47,XXX, with a triplication of the distal p arm of the X chromosome in the 47,XXX cells. Neither the triple mosaic nor the partial triplication was found among the controls. In another SS cohort, we found a mother/daughter pair with partial triplication of this same region of the X chromosome. The triple mosaic occurs in ~1 in 25,000–50,000 live female births, while partial triplications are even rarer. Conclusion: Very rare X chromosome abnormalities are present among patients with either SS or SLE and may inform the location of a gene(s) that mediates an X dose effect, as well as critical cell types in which such an effect is operative. © 2017, American College of Rheumatolog

Diseño de un Modelo de Operación para Ruteo de Transporte Urbano Basado en Simulación Discreta

Las grandes ciudades enfrentan una movilidad caótica producto del incremento del parque automotor, ocasionada por la falta planeación ante los nuevos sistemas de transporte. Un sistema de transporte ideal no se caracteriza por utilizar la totalidad de su capacidad en un único recorrido; sino por la disminución del uso de vehículos particulares. La participación de los Sistemas de Transporte Inteligente lo ha incrementado (Transantiago en Chile, y Transmetro en Barranquilla), aunque su implementación no garantiza el éxito en su operación; la sostenibilidad de las medianas y pequeñas empresas de transporte público pueden verse afectada. Por lo anterior, se propone de un modelo de simulación para una empresa de transporte de Barranquilla, Colombia, se determinan los aspectos internos y externos que pueden afectar al sistema, para determinar una solución subóptima, que permita mitigar el impacto social y financiero de la empresa en su entorno, se utilizan datos históricos-operacionales proporcionados por una empresa del rubro, así como un modelo de operación preliminar.AbstractThe Big cities face a chaotic mobility due to the increase of the fleet, caused by lack planning to new transport systems. An ideal transport system is not characterized by full use of its capacity in a single journey; but by reducing the use of private vehicles. The participation of Intelligent Transportation Systems has increased (Transantiago in Chile, and Transmetro in Barranquilla), but its implementation does not guarantee success in its operation; the sustainability of small and medium enterprises public transport may be affected. Therefore, it is proposed a simulation model for a transport company of Barranquilla, Colombia, internal and external aspects that can affect the system are determined, to determine an optimal solution that allows mitigate the social and financial impact of the company in its environment, historical and operational data provided by a company for the category as well as a preliminary operation model are used

Diseño de un Modelo de Operación para Ruteo de Transporte Urbano Basado en Simulación Discreta

Las grandes ciudades enfrentan una movilidad caótica producto del incremento del parque automotor, ocasionada por la falta planeación ante los nuevos sistemas de transporte. Un sistema de transporte ideal no se caracteriza por utilizar la totalidad de su capacidad en un único recorrido; sino por la disminución del uso de vehículos particulares. La participación de los Sistemas de Transporte Inteligente lo ha incrementado (Transantiago en Chile, y Transmetro en Barranquilla), aunque su implementación no garantiza el éxito en su operación; la sostenibilidad de las medianas y pequeñas empresas de transporte público pueden verse afectada. Por lo anterior, se propone de un modelo de simulación para una empresa de transporte de Barranquilla, Colombia, se determinan los aspectos internos y externos que pueden afectar al sistema, para determinar una solución subóptima, que permita mitigar el impacto social y financiero de la empresa en su entorno, se utilizan datos históricos-operacionales proporcionados por una empresa del rubro, así como un modelo de operación preliminar. Abstract The Big cities face a chaotic mobility due to the increase of the fleet, caused by lack planning to new transport systems. An ideal transport system is not characterized by full use of its capacity in a single journey; but by reducing the use of private vehicles. The participation of Intelligent Transportation Systems has increased (Transantiago in Chile, and Transmetro in Barranquilla), but its implementation does not guarantee success in its operation; the sustainability of small and medium enterprises public transport may be affected. Therefore, it is proposed a simulation model for a transport company of Barranquilla, Colombia, internal and external aspects that can affect the system are determined, to determine an optimal solution that allows mitigate the social and financial impact of the company in its environment, historical and operational data provided by a company for the category as well as a preliminary operation model are used